Cat. No.: HY-N6924

Zingibroside R1

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Zingibroside R1 is an orally active triterpene saponin with multiple biological activities including antioxidant, anti-inflammatory, antiviral, and metabolic regulatory properties. Zingibroside R1 reduces the expression of PIN family members, inhibits the expression of PLT1/PLT2, WOX5, SHR, and SCR, disrupts auxin transport and distribution, triggers plant ROS responses, and inhibits root growth. Zingibroside R1 extends the lifespan of Caenorhabditis elegans, enhances its heat stress resistance, and improves its motor ability. Hydrogel derivatives of Zingibroside R1 inhibit the proliferation of Candida albicans by binding to its β-1,3-glucan and exhibit antifungal activity. Zingibroside R1 inhibits GLUT1-mediated uptake and alleviates liver injury. Zingibroside R1 can be used in research related to neurodegenerative diseases, vulvovaginal candidiasis, acute liver injury, Ehrlich ascites tumor and HIV-1 infection.

For research use only. We do not sell to patients.

Purity: 99.47%
CAS No.: 80930-74-1
Formula: C₄₂H₆₆O₁₄
Molecular Weight:794.97

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Zingibroside R1 Chemical Structure

CAS No.: 80930-74-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[5]

HIV-1

GLUT1

All HIV Isoforms :

All GLUT Isoforms :

In Vitro

Zingibroside R1 (ZR1) (20-100 μM; 15-45 days) dose-dependently inhibits the adventitious root density and root apical meristem length of ginseng adventitious roots^[1].
Zingibroside R1 (5-10 μM; 2-7 days) dose-dependently inhibits primary root elongation, meristematic zone length, and elongation zone length in Arabidopsis thaliana Col-0 seedlings^[1].
Zingibroside R1 (5-10 μM; 2-7 days) reduces endogenous IAA levels in Arabidopsis thaliana and disrupts its polar auxin transport by decreasing the fluorescence intensity of specific PIN transporter markers^[1].
Zingibroside R1 (5-10 μM; 2-4 days) regulates the expression of core root stem cell regulators in Arabidopsis thaliana^[1].
Zingibroside R1 (5-10 μM; 7-10 days) induces oxidative stress in Arabidopsis thaliana Col-0 seedlings by promoting ROS accumulation, impairing the activity of ROS-scavenging enzymes, and altering the GSH/GSSG redox balance^[1].
Zingibroside R1 (2.0 wt%; 1 h heating, 30 min cooling, 6-24 h cell incubation) forms a stable hydrogel with shear recovery property, and exhibits excellent biocompatibility with human Caco-2 cells^[3].
Hydrogel containing 2.0 wt% Zingibroside R1 (ZR1), upon incubation for 2-24 h, potently inhibits the proliferation of Candida albicans in vitro by disrupting cell membrane integrity^[3].
Nanofibrils of Zingibroside R1 (100 ns simulation) exhibit high binding affinity for β-1,3-glucan in the cell wall of Candida albicans, and disrupt the integrity of fungal cell membranes through hydrogen bonding and structural perturbation^[3].
Zingibroside R1 (2.0 wt%; 24 h incubation) hydrogel can stably encapsulate Lactobacillus rhamnosus GG and achieve sustained release, while the LGG@ZR1 formulation exerts synergistic inhibitory effects on the proliferation of Candida albicans in vitro and acidifies the culture medium^[3].
Zingibroside R1 (compound 13) (10-100 μM; 10 min preincubation, 1 min uptake measurement) inhibits the uptake of 2-deoxyglucose (2-DG) by Ehrlich ascites tumor (EAT) cells, with an IC₅₀ of 91.3 μM, and acts as a partial competitive inhibitor of glucose transport^[5].
Zingibroside R1 (5 days) exhibits cytotoxicity (CC₅₀ = 46.2 μM) and anti-HIV-1 activity against the human T-cell line (MT-4)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Zingibroside R1 (4 µg/mL; incorporated into NGM agar plates and OP50 bacteria; continuous exposure from L4 larval stage through adulthood) extends the mean lifespan of N2 C. elegans by 10%, increases mean survival after heat stress by 12.1%, and improves multiple parameters of swimming behavior in aged nematodes^[2].
Zingibroside R1 (2% w/v; i.vag.; daily; 9 days) gel exhibits in vivo efficacy against vulvovaginal candidiasis in BALB/c mice, reducing fungal burden and vaginal inflammation^[3].
Zingibroside R1 (R1) (15-30 mg/kg; p.o.; daily; 7 days) exerts significant hepatoprotective effects against LPS/D-GalN-induced acute liver injury in male BALB/c mice by reducing oxidative stress, suppressing inflammation, modulating immune cell populations, restoring gut microbiota balance, and regulating hepatic metabolite profiles including succinic acid^[4].
Zingibroside R1 (30 mg/kg; oral; once daily; for 7 days) fecal microbiota transplantation in mice significantly ameliorates LPS/D-GalN-induced acute liver injury in male BALB/c mice by attenuating oxidative stress, inhibiting inflammatory responses, and restoring the hepatic metabolite profile including succinate^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (female, 18-20 g, vulvovaginal candidiasis model induced by subcutaneous estradiol benzoate followed by intravaginal C. albicans inoculation)^[3]
Dosage:

2% w/v
Administration:

i.vag.; daily; 9 days
Result:

Reduced C. albicans colony counts from vaginal washes throughout the treatment period.
Lessened epithelial disruption and neutrophil infiltration in vaginal tissues compared to untreated controls.
Showed gradual improvement in vaginal redness and inflammation by day 9.
Revealed residual fungal presence in vaginal tissues via PAS staining.

Animal Model:

BALB/c (male, 18-22 g, LPS/D-GalN-induced acute liver injury)^[4]
Dosage:

15 mg/kg; 30 mg/kg
Administration:

p.o.; daily; 7 days
Result:

Showed significant reduction in liver haemorrhaging, hepatocyte necrosis, nuclear shrinkage and inflammatory infiltration.
Decreased serum ALT and AST levels.
Reduced hepatic and serum ROS and MDA levels, and increased serum and hepatic SOD and GSH-Px activities.
Reduced hepatocyte apoptosis rate.
Decreased hepatic levels of TNF-α, IL-1β, IL-6 and IFN-γ, and increased IL-2 level.
Upregulated hepatic and peripheral blood Th cells, Tc cells, DCs and NK cells, and downregulated Tregs, macrophages (F4/80) and neutrophils (LY-6G).
Restored Shannon and Simpson indices, increased relative abundance of Ligilactobacillus, and decreased relative abundances of Clostridium and Anaerotignum.
Normalized liver metabolic profile, increased taurine, allose, L-carnitine, hypoxanthine, glycerol and 4-trimethylammoniobutanoic acid, and decreased succinic acid and D-lysine.

Animal Model:

BALB/c (male, 18-22 g, LPS/D-GalN-induced acute liver injury with faecal microbiota transplantation)^[4]
Dosage:

Faecal microbiota from mice treated with 30 mg/kg Zingibroside R1
Administration:

p.o.; daily; 6 days
Result:

Showed reduced hepatocyte necrosis, nuclear shrinkage and inflammatory cell infiltration compared to the M-FMT group.
Decreased serum ALT and AST levels relative to the M-FMT group.
Reduced hepatic ROS generation rate and hepatocyte apoptosis rate compared to the M-FMT group.
Normalized the liver metabolic profile, increased hypoxanthine and glycerophosphocholine, and decreased succinic acid relative to the M-FMT group.
Decreased hepatic levels of pro-inflammatory cytokines IL-1β, TNF-α, IL-6 and IFN-γ compared to the M-FMT group.

Chemical Information

CAS No. 80930-74-1
Appearance Solid
Molecular Weight 794.97
Formula C₄₂H₆₆O₁₄
Color White to off-white
SMILES

C[C@@]12C([C@@]3([H])[C@](C(O)=O)(CCC(C)(C)C3)CC2)=CC[C@]4([H])[C@@](C)(CC[C@H](O[C@@]5([H])[C@@H]([C@H]([C@H](O)[C@@H](C(O)=O)O5)O)O[C@]6([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)CO)C7(C)C)[C@@]7([H])CC[C@@]14C
Structure Classification
- Saccharides
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (125.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2579 mL

6.2895 mL

12.5791 mL

5 mM

0.2516 mL

1.2579 mL

2.5158 mL

10 mM

0.1258 mL

0.6290 mL

1.2579 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (302 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang X, et al. Panax-derived Zingibroside R1 exerts allelopathic effects on root architecture by modulating the auxin transport pathway and oxidative stress responses. Horticulture Research, 2026, uhag185.

[2]. Sayed S. M. A., et al. Identification of a Hydroxygallic Acid Derivative, Zingibroside R1 and a Sterol Lipid as Potential Active Ingredients of Cuscuta chinensis Extract That Has Neuroprotective and Antioxidant Effects in Aged Caenorhabditis elegans. Nutrients, 2022, 14(19): 4199.

[3]. Peng M, et al. Atomic Insights Into Self-Assembly of Zingibroside R1 and its Therapeutic Action Against Fungal Diseases. Adv Mater. 2025;37(26):e2503283. [Content Brief]

[4]. Guo P, et al. Zingibroside R1 Isolated From Achyranthes bidentata Blume Ameliorates LPS/D-GalN-Induced Liver Injury by Regulating Succinic Acid Metabolism via the Gut Microbiota. Phytother Res. 2025;39(10):4520-4534. [Content Brief]

[5]. Hasegawa H, et al. Inhibitory effect of some triterpenoid saponins on glucose transport in tumor cells and its application to in vitro cytotoxic and antiviral activities. Planta Med. 1994;60(3):240-243. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2579 mL	6.2895 mL	12.5791 mL	31.4477 mL
	5 mM	0.2516 mL	1.2579 mL	2.5158 mL	6.2895 mL
	10 mM	0.1258 mL	0.6290 mL	1.2579 mL	3.1448 mL
	15 mM	0.0839 mL	0.4193 mL	0.8386 mL	2.0965 mL
	20 mM	0.0629 mL	0.3145 mL	0.6290 mL	1.5724 mL
	25 mM	0.0503 mL	0.2516 mL	0.5032 mL	1.2579 mL
	30 mM	0.0419 mL	0.2097 mL	0.4193 mL	1.0483 mL
	40 mM	0.0314 mL	0.1572 mL	0.3145 mL	0.7862 mL
	50 mM	0.0252 mL	0.1258 mL	0.2516 mL	0.6290 mL
	60 mM	0.0210 mL	0.1048 mL	0.2097 mL	0.5241 mL
	80 mM	0.0157 mL	0.0786 mL	0.1572 mL	0.3931 mL
	100 mM	0.0126 mL	0.0629 mL	0.1258 mL	0.3145 mL

Zingibroside R1

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Zingibroside R1

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Antifungal Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Glucose Metabolism Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Zingibroside R1

All HIV Isoforms

All GLUT Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Zingibroside R1 Related Classifications

Cat. No.: HY-N6924